Loading...

FDA Approves Additional COVID Vaccine Dose for Some Individuals

August 13, 2021 by TWN Staff
FDA Approves Additional COVID Vaccine Dose for Some Individuals
A vial of the Pfizer COVID-19 vaccine. (Photo by Dan McCue)

The Food and Drug Administration has authorized the use of an additional dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines for organ transplant recipients diagnosed as immunocompromised.

Thursday’s announcement came ahead of a meeting today of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices.

At that meeting, the advisory panel voted 11-0 to endorse giving third doses of mRNA vaccines to people with moderately to severely weakened immune systems.

“The country has entered yet another wave of the COVID-19 pandemic, and the FDA is especially cognizant that immunocompromised people are particularly at risk for severe disease,” said Acting FDA Commissioner Janet Woodcock, M.D. in a written statement. “After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines.” 

Woodcock went on to say Thursday’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19. 

“As we’ve previously stated, other individuals who are fully vaccinated are adequately protected and do not need an additional dose of COVID-19 vaccine at this time. The FDA is actively engaged in a science-based, rigorous process with our federal partners to consider whether an additional dose may be needed in the future,” Woodcock said.

People who are immunocompromised in a manner similar to those who have undergone solid organ transplantation have a reduced ability to fight infections and other diseases, and they are especially vulnerable to infections, including COVID-19. 

The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna vaccines in these individuals and determined that the administration of third vaccine doses may increase protection in this population. These patients should be counseled to maintain physical precautions to help prevent COVID-19. 

In addition, close contacts of immunocompromised persons should get vaccinated, as appropriate for their health status, to provide increased protection to their loved ones.

The Pfizer-BioNTech COVID-19 vaccine is currently authorized for emergency use in individuals ages 12 and older, and the Moderna COVID-19 vaccine is authorized for emergency use in individuals ages 18 and older. 

Both vaccines are administered as a series of two shots: the Pfizer-BioNTech vaccine shots are administered three weeks apart, and the Moderna vaccine shots are administered one month apart. 

The authorizations for these vaccines have been amended to allow for an additional, or third, dose to be administered at least 28 days following the two-dose regimen of the same vaccine to individuals 18 years of age or older (ages 12 or older for Pfizer-BioNTech) who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

In The News

Health

Voting

Health

January 26, 2022
by Alexa Hornbeck
EPA and WHO Sign Memorandum With New Actions to Protect Human Health

The U.S. Environmental Protection Agency and World Health Organization recently signed a five-year Memorandum of Understanding with new actions for protecting human health... Read More

The U.S. Environmental Protection Agency and World Health Organization recently signed a five-year Memorandum of Understanding with new actions for protecting human health and the environment. “The COVID-19 pandemic has highlighted the intimate links between humans and our environment,” said Dr. Tedros Adhanom Ghebreyesus, WHO director-general, in a written statement. ... Read More

January 26, 2022
by Alexa Hornbeck
Black Patients With Dementia More Likely to Receive Aggressive Care in Nursing Homes 

A recent study published in JAMA Internal Medicine shows that Black nursing home residents with advanced dementia likely receive more aggressive care... Read More

A recent study published in JAMA Internal Medicine shows that Black nursing home residents with advanced dementia likely receive more aggressive care than non-Black residents.  A team of researchers from Massachusetts, Tennessee, Georgia and North Carolina conducted the qualitative study with 169 staff interviews in 14 nursing homes... Read More

January 26, 2022
by Alexa Hornbeck
UCSD Offers Magnetic Stimulation for Patients With Treatment-Resistant Depression 

The University of California San Diego Health now offers a new treatment for patients with treatment-resistant depression, called transcranial magnetic stimulation.... Read More

The University of California San Diego Health now offers a new treatment for patients with treatment-resistant depression, called transcranial magnetic stimulation. TMS is a treatment approved by the U.S. Food and Drug Administration to stimulate nerve cells in areas of the brain associated with major depression. The... Read More

January 26, 2022
by Alexa Hornbeck
Rhode Island Delays Enforcement of Law to Increase Staffing in Nursing Homes 

In Rhode Island, Gov. Dan McKee recently signed an executive order to halt the enforcement of the Nursing Home Staffing and Quality Care... Read More

In Rhode Island, Gov. Dan McKee recently signed an executive order to halt the enforcement of the Nursing Home Staffing and Quality Care Act, which he signed into law last May to give nursing homes across the state a higher staff-to-patient ratio.  The Nursing Home Staffing and Quality Care... Read More

January 26, 2022
by Alexa Hornbeck
Yale Researchers Develop a Fresh Air Clip Capable of Detecting Virus 

Researchers from the Yale School of Public Health recently developed a small, lightweight, inexpensive wearable device — the Fresh Air Clip —... Read More

Researchers from the Yale School of Public Health recently developed a small, lightweight, inexpensive wearable device — the Fresh Air Clip — that is capable of detecting possible exposure to SARS-CoV-2. The clip was developed to help individuals in high-risk settings to detect low levels of virus and... Read More

January 26, 2022
by Alexa Hornbeck
Pfizer-BioNTech Prepare to Revise Vaccine Formula for Omicron Variant

On Tuesday, Pfizer-BioNTech announced they will begin a clinical trial to develop an omicron-specific COVID-19 vaccine candidate.  “Emerging data indicate vaccine-induced protection... Read More

On Tuesday, Pfizer-BioNTech announced they will begin a clinical trial to develop an omicron-specific COVID-19 vaccine candidate.  “Emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains,” said Prof. Ugur Sahin, CEO and co-founder of BioNTech, in... Read More

News From The Well
Exit mobile version